UA118369C2 - Сполуки, що інгібують активність lrrk2 кінази - Google Patents

Сполуки, що інгібують активність lrrk2 кінази Download PDF

Info

Publication number
UA118369C2
UA118369C2 UAA201609099A UAA201609099A UA118369C2 UA 118369 C2 UA118369 C2 UA 118369C2 UA A201609099 A UAA201609099 A UA A201609099A UA A201609099 A UAA201609099 A UA A201609099A UA 118369 C2 UA118369 C2 UA 118369C2
Authority
UA
Ukraine
Prior art keywords
mmol
rhms
pharmaceutically acceptable
methyl
compound
Prior art date
Application number
UAA201609099A
Other languages
English (en)
Ukrainian (uk)
Inventor
Сяо Дін
Цянь ЛЮ
Інся Сан
Луїджи П'єро Стазі
Цзехун Вань
Баовей Чжао
Колін Майкл Едж
Original Assignee
Глаксосмітклайн Інтеллектьюел Проперті Девелопмент Лімітед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Глаксосмітклайн Інтеллектьюел Проперті Девелопмент Лімітед filed Critical Глаксосмітклайн Інтеллектьюел Проперті Девелопмент Лімітед
Publication of UA118369C2 publication Critical patent/UA118369C2/uk

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
UAA201609099A 2014-01-29 2015-01-28 Сполуки, що інгібують активність lrrk2 кінази UA118369C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN2014000139 2014-01-29
PCT/CN2015/000055 WO2015113452A1 (en) 2014-01-29 2015-01-28 Compounds

Publications (1)

Publication Number Publication Date
UA118369C2 true UA118369C2 (uk) 2019-01-10

Family

ID=53756224

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201609099A UA118369C2 (uk) 2014-01-29 2015-01-28 Сполуки, що інгібують активність lrrk2 кінази

Country Status (20)

Country Link
US (2) US10087186B2 (2)
EP (1) EP3099695B1 (2)
JP (1) JP6422986B2 (2)
KR (1) KR20160106622A (2)
CN (1) CN105940004B (2)
AU (2) AU2015210593A1 (2)
CA (1) CA2937431A1 (2)
CL (1) CL2016001895A1 (2)
CR (1) CR20160348A (2)
DO (2) DOP2016000195A (2)
EA (1) EA029774B1 (2)
ES (1) ES2802174T3 (2)
IL (1) IL246579B (2)
MA (1) MA39219B1 (2)
MX (1) MX367370B (2)
PE (1) PE20161443A1 (2)
PH (1) PH12016501307B1 (2)
SG (1) SG11201605342UA (2)
UA (1) UA118369C2 (2)
WO (1) WO2015113452A1 (2)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10339791B2 (en) 2007-06-12 2019-07-02 Icontrol Networks, Inc. Security network integrated with premise security system
RU2016134751A (ru) 2014-01-29 2018-03-02 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Соединения
MA39219B1 (fr) 2014-01-29 2018-11-30 Glaxosmithkline Ip Dev Ltd Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique
CN105153131B (zh) * 2015-09-21 2017-10-17 马彦丽 一种在护理上治疗人神经胶质瘤的药物组合物
CN105348270B (zh) * 2015-11-09 2018-01-09 吕显艳 一种防治牙体牙髓感染的药物组合物
US11214565B2 (en) 2015-11-20 2022-01-04 Denali Therapeutics Inc. Compound, compositions, and methods
JP2018537502A (ja) 2015-12-16 2018-12-20 サウザーン リサーチ インスチチュート ピロロピリミジン化合物、キナーゼｌｒｒｋ２阻害剤としての使用、及びその調製方法
CN105418616B (zh) * 2015-12-26 2018-01-12 山东大学 一种含有 4‑氨基吡唑结构的jak 激酶抑制剂及其制备方法和应用
US11028080B2 (en) 2016-03-11 2021-06-08 Denali Therapeutics Inc. Substituted pyrimidines as LRKK2 inhibitors
SMT202100699T1 (it) 2016-06-16 2022-01-10 Denali Therapeutics Inc Pirimidin-2-ilammino-1h-pirazoli come inibitori di lrrk2 per l'uso nel trattamento di disturbi neurodegenerativi
JP2020505398A (ja) * 2017-01-25 2020-02-20 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 化合物
EP3587422A4 (en) * 2017-02-22 2020-05-06 Daegu-Gyeongbuk Medical Innovation Foundation PYRROLOPYRIMIDINE DERIVATIVE COMPOUND, PRODUCTION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION WITH THIS COMPOUND AS AN ACTIVE SUBSTANCE FOR PREVENTING OR TREATING PROTEIN KINASE-RELATED DISEASE
CN110662745B (zh) * 2017-03-23 2021-08-03 大邱庆北尖端医疗产业振兴财团 吡咯并吡啶衍生物、其制备方法、和用于预防或治疗蛋白激酶相关疾病的药物组合物
AU2018381574B2 (en) * 2017-12-05 2022-09-15 Oscotec Inc. Pyrrolo(pyrazolo)pyrimidine derivative as LRRK2 inhibitor
CN108715834B (zh) * 2018-06-01 2021-09-14 天晴干细胞股份有限公司 一种富含cd41+、cd81+微囊的血小板裂解液制备方法
WO2020036437A1 (ko) * 2018-08-16 2020-02-20 재단법인 대구경북첨단의료산업진흥재단 치환된 헤테로아릴 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 단백질 키나아제 관련 질환의 예방 또는 치료용 약학적 조성물
JP7447098B2 (ja) * 2018-09-25 2024-03-11 カーデュリオン・ファーマシューティカルズ・インコーポレイテッド アミノピリミジン化合物
EP3915985A4 (en) 2019-01-18 2022-09-28 Voronoi Co., Ltd. PYRROLOPYRIDE DERIVATIVE AND USE THEREOF FOR THE PREVENTION AND TREATMENT OF PROTEIN KINASE RELATED DISEASES
CZ308800B6 (cs) 2019-02-12 2021-05-26 Univerzita Palackého v Olomouci Heterocyklické dusíkaté deriváty purinu, farmaceutické přípravky obsahující tyto deriváty a jejich použití při neuroprotekci
EP4236950A4 (en) 2020-10-29 2024-10-23 Merck Sharp & Dohme LLC N-LINKED ISOQUINOLINE AMIDES AS LRRK2 INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND USES THEREOF
EP4238975A4 (en) * 2020-10-29 2024-06-12 Suzhou Yabao Pharmaceutical R&D Co., Ltd. SUBSTITUTED DIARYLAMINE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, MANUFACTURING PROCESS THEREOF AND USE THEREOF
KR20220081631A (ko) 2020-12-09 2022-06-16 보로노이 주식회사 염증성 질환의 예방 및/또는 치료를 위한 피롤로-피리딘 유도체 화합물의 신규 용도
JP2024541934A (ja) 2021-10-27 2024-11-13 ハー・ルンドベック・アクチエゼルスカベット Ｌｒｒｋ２阻害剤
WO2023076404A1 (en) 2021-10-27 2023-05-04 Aria Pharmaceuticals, Inc. Methods for treating systemic lupus erythematosus
TW202412777A (zh) 2022-09-15 2024-04-01 丹麥商Ｈ 朗德貝克公司 富白胺酸重複激酶2（lrrk2）抑制劑

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2537916A1 (en) 2003-09-03 2005-03-31 Neurogen Corporation 5-aryl-pyrazolo[4,3-d]pyrimidines, pyridines, and pyrazines and related compounds
GB0420719D0 (en) 2004-09-17 2004-10-20 Addex Pharmaceuticals Sa Novel allosteric modulators
US8029986B2 (en) 2004-10-21 2011-10-04 Helmholtz Zentrum Muenchen Deutsches Forschungszentrum fuer Gesundheit und Umwelt(GmbH) KASPP (LRRK2) gene, its production and use for the detection and treatment of neurodegenerative disorders
WO2006050076A1 (en) 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders
NO323175B1 (no) 2004-12-23 2007-01-15 Jan O Aasly Framgangsmate for a pavise en mutasjon som forarsaker arvelig parkinsonisme
JP2009511528A (ja) 2005-10-13 2009-03-19 グラクソ グループ リミテッド Ｓｙｋ阻害物質としてのピロロピリミジン誘導体群
CA2651072A1 (en) 2006-05-01 2007-11-08 Pfizer Products Inc. Substituted 2-amino-fused heterocyclic compounds
WO2009036066A1 (en) 2007-09-10 2009-03-19 Curis, Inc. Vegfr inhibitors containing a zinc binding moiety
US9315449B2 (en) 2008-05-15 2016-04-19 Duke University Substituted pyrazoles as heat shock transcription factor activators
WO2009143018A2 (en) 2008-05-19 2009-11-26 Plexxikon, Inc. Compounds and methods for kinase modulation, and indications therefor
WO2009143404A1 (en) 2008-05-23 2009-11-26 Wyeth Piperazine metabotropic glutamate receptor 5 (mglur5) negative allosteric modulators for anxiety/depression
US9908884B2 (en) 2009-05-05 2018-03-06 Dana-Farber Cancer Institute, Inc. EGFR inhibitors and methods of treating disorders
JP5752691B2 (ja) 2009-09-29 2015-07-22 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ 新規化合物
WO2011153553A2 (en) 2010-06-04 2011-12-08 The Regents Of The University Of California Methods and compositions for kinase inhibition
WO2012009258A2 (en) 2010-07-13 2012-01-19 Edward Roberts Peptidomimetic galanin receptor modulators
WO2012045195A1 (en) 2010-10-09 2012-04-12 Abbott Laboratories Pyrrolopyrimidines as fak and alk inhibiters for treatment of cancers and other diseases
NO2638031T3 (2) * 2010-11-10 2018-03-10
JP2013545749A (ja) 2010-11-10 2013-12-26 インフィニティー ファーマシューティカルズ， インコーポレイテッド 複素環化合物及びその使用
WO2012080729A2 (en) 2010-12-14 2012-06-21 Electrophoretics Limited CASEIN KINASE 1δ (CK1δ) INHIBITORS
AP2013007253A0 (en) 2011-04-21 2013-11-30 Origenis Gmbh Pyrazolo [4,3-D] pyrimidines useful as kinase inhibitors
EP2758402B9 (en) 2011-09-22 2016-09-14 Pfizer Inc Pyrrolopyrimidine and purine derivatives
EP2785381B1 (en) * 2011-11-30 2016-05-18 F.Hoffmann-La Roche Ag Fluorine-18 and carbon-11 labeled radioligands for positron emission tomography (pet) imaging for lrrk2
GB201204985D0 (en) * 2012-03-21 2012-05-02 Genentech Inc Compounds
EP2844652B1 (en) 2012-05-03 2019-03-13 Genentech, Inc. Pyrazole aminopyrimidine derivatives as lrrk2 modulators
KR102091895B1 (ko) 2012-05-03 2020-04-14 제넨테크, 인크. 파킨슨병의 치료에 사용하기 위한 lrrk2 조절제로서의 피라졸 아미노피리미딘 유도체
EP2867236B1 (en) 2012-06-29 2017-06-14 Pfizer Inc Novel 4-(substituted-amino)-7h-pyrrolo[2,3-d]pyrimidines as lrrk2 inhibitors
RU2016134751A (ru) 2014-01-29 2018-03-02 Глэксосмитклайн Интеллекчуал Проперти Дивелопмент Лимитед Соединения
MA39219B1 (fr) 2014-01-29 2018-11-30 Glaxosmithkline Ip Dev Ltd Nouveaux composés inhibiteurs de la kinase lrrk2 utilisés pour le traitement du parkinson, de l’alzheimer et de la sclérose latérale amyotrophique

Also Published As

Publication number Publication date
PE20161443A1 (es) 2017-01-06
AU2015210593A1 (en) 2016-07-07
PH12016501307A1 (en) 2016-08-15
US10087186B2 (en) 2018-10-02
JP6422986B2 (ja) 2018-11-14
DOP2016000195A (es) 2016-10-31
EP3099695A4 (en) 2017-07-12
US20180354956A1 (en) 2018-12-13
IL246579B (en) 2019-05-30
EA201691514A1 (ru) 2016-12-30
IL246579A0 (en) 2016-08-31
EA029774B1 (ru) 2018-05-31
EP3099695A1 (en) 2016-12-07
CA2937431A1 (en) 2015-08-06
CR20160348A (es) 2017-04-28
MA39219B1 (fr) 2018-11-30
CN105940004A (zh) 2016-09-14
CL2016001895A1 (es) 2016-12-09
US10618901B2 (en) 2020-04-14
ES2802174T3 (es) 2021-01-15
JP2017504631A (ja) 2017-02-09
KR20160106622A (ko) 2016-09-12
WO2015113452A1 (en) 2015-08-06
SG11201605342UA (en) 2016-08-30
AU2018200277B2 (en) 2019-09-26
DOP2019000010A (es) 2019-03-15
US20170015668A1 (en) 2017-01-19
AU2018200277A1 (en) 2018-02-01
MA39219A1 (fr) 2017-09-29
PH12016501307B1 (en) 2016-08-15
MX2016009893A (es) 2016-10-31
EP3099695B1 (en) 2020-04-08
CN105940004B (zh) 2018-02-02
MX367370B (es) 2019-08-16

Similar Documents

Publication Publication Date Title
UA118369C2 (uk) Сполуки, що інгібують активність lrrk2 кінази
AU2020267169B2 (en) Processes of making and crystalline forms of a MDM2 inhibitor
JP5792279B2 (ja) ジスピロピロリジン誘導体
CA2861150C (en) Morphinan derivative
EP3227297B1 (en) 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors
KR102672512B1 (ko) 항바이러스 피리도피라진디온 화합물
UA123689C2 (uk) Імідазопіролопіридинові сполуки як інгібітори кіназ родини jак
UA125824C2 (uk) 6,7,8,9-ТЕТРАГІДРО-3H-ПІРАЗОЛО[4,3-f]ІЗОХІНОЛІНОВІ ПОХІДНІ, ЗАСТОСОВНІ В ЛІКУВАННІ РАКУ
JPWO2009151069A1 (ja) ４，７−ジアザスピロ［２．５］オクタン環構造を有するイミダゾチアゾール誘導体
JP2021519266A (ja) ３−ヒドロキシ−Ｎ−（３−（７Ｈ−ピロロ［２，３−ｄ］ピリミジン−４−イル）フェニル）ピロリジン−１−カルボキサミド誘導体
TW201107325A (en) Nitrogen-containing spiro cyclic compounds and pharmaceutical use thereof
TW201120040A (en) Bruton's tyrosine kinase inhibitors
EA024171B1 (ru) Ингибиторы вируса гепатита с
JP5520236B2 (ja) プロリン環構造を有するイミダゾチアゾール誘導体
US11667613B2 (en) Antiviral pyrazolopyridinone compounds
EP3889138A1 (en) Histone acetylase p300 inhibitor and use thereof
EP3576743B1 (en) 5-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-5-azaspiro[2 5]octane-8-carboxylic acid derivatives as jak kinase inhibitors
RU2803284C1 (ru) Производные бензимидазола
JP2012036181A (ja) プロリン環構造を有するイミダゾチアゾール誘導体
HK40081050A (en) Benzimidazole derivatives
EA047837B1 (ru) Аналоги бензоазепина в качестве ингибирующих агентов для тирозинкиназы брутона
HK1226052B (en) Crystalline form of a mdm2 inhibitor
HK1226052A1 (en) Crystalline form of a mdm2 inhibitor
HK1238236B (en) 4,6-substituted-pyrazolo[1,5-a]pyrazines as janus kinase inhibitors
NZ614218B2 (en) Dispiropyrrolidine derivatives